Award Number: DAMD17-99-1-9123

TITLE: Molecular Markers in Hereditary Breast Cancer

PRINCIPAL INVESTIGATOR: Olufunmilayo I. Olopade, M.D.

CONTRACTING ORGANIZATION: The University of Chicago
Chicago, Illinois 60637

REPORT DATE: October 2003

TYPE OF REPORT: Final Addendum

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.
Molecular Markers in Hereditary Breast Cancer

Olufunmilayo I. Olopade, M.D.

The University of Chicago
Chicago, Illinois 60637

E-Mail: folopade@medicine.bsd.uchicago.edu

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited

We are entering a new era of medicine where genetic markers are going to be used to make clinical management decisions. My long term career goal is to further our understanding of the genetic alterations which characterize human breast cancer in a way that will eventually lead to early diagnosis, more effective treatment or prevention of the disease. The promise of research into breast cancer genetics is that it will provide us with new insight into the etiology of breast cancer that can be translated to strategies for early diagnosis and treatment for the larger population of women who develop breast cancer without having a genetic predisposition.
# Table of Contents

Cover .................................................................................................................. 1
SF 298 .................................................................................................................. 2
Table of Contents ................................................................................................. 3
Introduction .......................................................................................................... 4
Body ....................................................................................................................... 4-6
Key Research Accomplishments .......................................................................... 7
Reportable Outcomes ............................................................................................. 7
Conclusions .......................................................................................................... 7
References ........................................................................................................... 8
Appendices .......................................................................................................... NA
INTRODUCTION

As a physician-scientist, I have had extensive training in clinical oncology and in molecular biology and genetics; I am ideally positioned to bridge the gap between the two. The academic award has represented an outstanding opportunity for me to critically appraise the emerging role of genetics in clinical breast cancer care and forge new avenues of research. Toward this goal, I plan to accomplish the following during the period of my academic award.

1) perform a thorough review of the cytogenetic and molecular genetics literature to identify potential chromosomal regions that may harbor genes whose abnormal function is critically involved in the development of breast cancer.

2) develop a robust panel of markers that can be used for clinical correlative studies of hereditary breast cancers.

3) develop a tissue repository composed of biological specimens from 500 patients with inherited breast cancer (e.g. fresh frozen tumor specimens, or paraffin embedded tumor specimens and normal blood lymphocytes, DNA and sera whenever possible).

Using these unique resources, my future studies will characterize the molecular pathways that allow a normal breast cell to become cancerous in individuals who are genetically predisposed. I will also develop longitudinal follow up studies to correlate clinical outcomes with molecular characterization and epidemiologic risk factors. These studies will no doubt lead to an improved understanding of the biology of breast cancer, which will ultimately translate into more effective therapies.

Task I

Perform a thorough review of the cytogenetic and molecular genetics literature to identify potential chromosomal regions that may harbor genes whose abnormal function is critically involved in the development of breast cancer.

This year we published three reviews, one book chapter, have one pending review, and one pending book chapter on the genetics of breast cancer. Thus we have completed Task I.

Publications


Fackenthal, JD and Olopade, OI (in press for Endocrine-Related Cancer). Cancer genetics of BRCA1 and BRCA2.


**Task II**

**Develop a robust panel of markers that can be used for clinical correlative studies of hereditary breast cancers.**

We have developed several probes for fluorescent in situ hybridization as well as optimized the conditions for several antibodies, which we have now applied to a well characterized panel of tumors in our tumor bank. Task II is completed and our findings are summarized below.

**a) Dissection of Cooperating Oncogenes involved in BRCA1 tumor progression**

To examine whether amplification of HER-2/neu contributes to the aggressive biology of BRCA1-associated tumors, we performed fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-embedded breast tumor tissue sections from 53 BRCA1 mutation carriers and 41 randomly selected age-matched sporadic breast cancer cases. Although BRCA1-associated and sporadic tumors were equally likely (19% versus 22%) to exhibit HER-2/neu amplification (defined as a ratio of HER-2/neu copies to chromosome 17 centromere (CEP17) copies ≥ 2), 6 (15%) of the sporadic tumors were highly amplified (defined as a ratio ≥ 5) versus none of the BRCA1-associated tumors (p= 0.048). HER-2 protein overexpression as measured by immunohistochemical analysis (IHC) was not observed among the BRCA1-associated cases (p = 0.042). Four out of 21 (19%) sporadic tumors exhibited strong membranous staining of HER-2 (intensity level of 3+) as compared to 0/39 BRCA1-associated tumors. Our data suggest that a germ line mutation in the BRCA1 tumor suppressor gene is associated with a significantly lower level of HER-2/neu amplification. Thus, it is possible that BRCA1- associated and HER-2/neu- highly amplified tumors progress through distinct molecular pathways and the aggressive pathologic features of BRCA1-associated tumors appear unrelated to amplification of the adjacent HER-2/neu oncogene (Grushko et al. 2002).

Using breast tumor tissues from a relatively large cohort of 102 women including 40 with deleterious BRCA1 mutations and molecular cytogenetics techniques, we tested the hypothesis that the presence of a germ line BRCA1 mutation might be associated with MYC amplification in somatic tumor cells. We observed a MYC/CEP8 amplification ratio ≥2 in 21 of 40 (53%) BRCA1-mutated compared to 14 of 62 (23%) sporadic tumors (P=0.003). Of interest, 8 (57%) of the 14 sporadic cases with MYC amplification were BRCA1-methylated. In total, MYC amplification was found in the majority of tumors with inactivated BRCA1 and at a higher frequency than in tumors without loss of BRCA1 (29/60, 48% versus 6/42, 14%; p=0.0003). Thus, our study confirms for the first time in a larger panel of tumors, data from DNA microarray studies that suggest that breast cancers arising in the setting of germ line BRCA1 mutations have unique gene expression profiles, and sporadic tumors with methylated BRCA1 may be misclassified with the BRCA1-mutation-positive group.

The importance of this work is to suggest that the aggressive features of BRCA1-associated tumors are in part due to MYC oncogenic activity and that MYC amplification contributes to tumor progression in both hereditary and sporadic BRCA1-deficient cells. This obviously has implications for understanding the molecular mechanisms for de novo gene amplification as well as for developing new drug targets. To our knowledge, this is the first comprehensive study of MYC gene amplification
in BRCA1-associated tumors using molecular-cytogenetic techniques. The manuscript has been accepted for publication in Clinical Cancer Research.

b) Hypermethylation of BRCA1 and ER promoter

We assessed BRCA1 and estrogen receptor (ER) promoter methylation in 5 breast cancer cell lines and 132 primary breast tissues by Methylation-Specific (M-PCR). BRCA1 and ER expression were determined in breast tumor cell lines and primary tissues by RT-PCR. In addition, we performed FISH using BRCA1 and CEP17 probes on both sporadic and BRCA1-associated hereditary breast cancer. We observed BRCA1 methylation in the UACC-3199 positive control cell line and in 39 of 132 sporadic (29.5%) tumors. BRCA1 methylation was correlated with chromosome 17 aneusomy and down-regulation or complete absence of the transcript. BRCA1 methylation correlated inversely with age of onset: 40% of tumors from cases under 55 years old were methylated vs. 25% of cases over 55 years old (Table 4). The methylated cases were equally distributed among all histological types and there was no difference in the proportion of African American women (27.5%) vs. non-Hispanic White women with methylated tumors (28.6%). The majority of BRCA1-methylated cases (79%) were ER (-) and/or ER methylated. MYC and HER2/neu amplification in methylated tumors were intermediate in values between hereditary BRCA1-associated and sporadic unmethylated tumors, suggesting that BRCA1 methylation might be incomplete in some tumors. These results suggest that silencing of the BRCA1 gene by methylation occurs in a significant proportion of sporadic breast cancers and may be an early event during tumor progression (Wei et al. AACR 2003 abstract). There may be a slight difference in the proportion of black women with methylated tumors.

Publications


Task III

Develop a tissue repository composed of biological specimens from 500 patients with familial or hereditary breast cancer (e.g. fresh frozen tumor specimens, or paraffin embedded tumor specimens and normal blood lymphocytes, DNA and sera whenever possible).

After several delayed attempts to get approval for a clinical protocol for the tumor bank from the army despite approval from our local IRB, we have enrolled 25 patients. Due to low accrual despite the one year no cost extension provided to us last year, we wish to terminate the protocol as it is no longer viable.
KEY RESEARCH ACCOMPLISHMENTS:

We are defining important pathways in inherited BRCA1-associated breast cancer tumor progression.

REPORTABLE OUTCOMES:

Based on this academic award from the Army, I am now a full-fledged breast cancer researcher. This work has led to two RO1s funded by the National Institutes of Health.


CONCLUSIONS:

The observed similarities in molecular pathogenesis between BRCA1-mutated and BRCA1-methylated tumors led us to propose a tumor progression model in which early loss of BRCA1 causes defects in chromosome structure, cell division, and viability, so that a BRCA1-deficient cell must acquire additional alterations that overcome these problems and presumably force tumor evolution down a limited set of pathways. Our FISH results are consistent with data from DNA microarray studies that suggest that breast cancers arising in the setting of germ line BRCA1 mutations have unique gene expression profiles, and sporadic tumors with methylated BRCA1 may be misclassified with the BRCA1-mutation-positive group. A review of the set of genes published by Hedenfalk et al. (Hedenfalk et al. 2001) and in the paper by van ‘t Veer et al. (van ‘t Veer et al. 2002) demonstrated that MYC on 8q was overexpressed in BRCA1 mutation carriers. In addition, the BRCA1 mutant tumors we have studied appear to have a profile that is most consistent with the basal-like subtype suggested by Perou et al. (Perou et al. 2000), based on the following observations. First, both (meaning sporadic basal-like tumors and BRCA1 mutant tumors) tend to be high grade, ER/PR negative and HER2/neu-negative, and both show the high expression and/or amplification of MYC. In fact, MYC emerged as one of the most relevant genes that defined the basal-like group and was expressed more than 2-4 fold above background in the majority of cases (Perou, unpublished results). Moreover, we have shown that BRCA1-mutated tumors express specific basal cytokeratins in a manner suggestive of an ER-negative basal-like epithelial cell of origin (Olopade and Grushko 2001) and are never associated with high levels of HER-2/neu amplification (Grushko et al. 2002). Therefore, it is reasonable to suggest that BRCA1-mutated tumors are mostly basal-like (ER-, HER2-) and that MYC amplification/overexpression further defines BRCA1-deficient tumor cells.
REFERENCES:


APPENDICES:

N/A